… plus obinutuzumab [Gazyva] or rituximab [Rituxan] as their next … in the College of Medicine at The Ohio State … indicated by the FDA for the treatment of adult patients … ;www.fda.gov/drugs/;resources-information-approved-drugs/fda-grants-accelerated …

… of rituximab and targeted care on treatment outcomes. This randomized controlled trial, conducted … randomized controlled design of the trials adds robustness to the findings … , it is incumbent upon the medical community to harness such insights …

… -label, blinded-end point multicenter trial conducted in Norway. The study … from a target trial emulation, which demonstrated that rituximab had superior efficacy … the treatment of MS but act through distinct mechanisms as rituximab targets …

… are a lot of different trials going on trying to use … , highlighting the importance of balancing treatment efficacy with long-term safety … J, et al. Rituximab long-term DOSE trial in Multiple Sclerosis – RIDOSE …

… -mg rituximab was as effective as the conventional 6-monthly treatment regimen … from the RIFUND-MS trial (NCT02746744), which demonstrated rituximab’s superiority over … -blinded, phase 3, randomised controlled trial. Lancet Neurol. 2022;21(8 …

… MD The phase 3 TRANSFORM trial (NCT03575351) assessed lisocabtagene … reported results in the treatment-emergent (TE) period. … by all the randomized trials is patients who … with polatuzumab vedotin (Polivy), rituximab, cyclophosphamide, doxorubicin, and …

… the phase 3 CLL14 trial (NCT02242942) demonstrated that … from prospectively designed clinical trials, indirect comparisons can … 47;ethnicity, age, and medical comorbidities. In addition, … bendamustine and rituximab in patients with treatment-naïve chronic …

… professor of medicine at The Warren Alpert Medical School of … relapsing soon after completing their [rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine … first-line treatment. This trial, [unlike] some other recently reported trials, enrolled …

… Tiantan Hospital, Capital Medical University, the trial aimed to evaluate efficacy … a treatment for relapsing multiple sclerosis (MS). Like rituximab and inebilizumab, medications both … in large-scale NMOSD trials. READ MORE: FDA Extends Review Time for …

… Medicine (Hematology) at Yale University. Transcript: The current treatment … changed among most lymphoma doctors. That is based off … rituximab as a standard combination, although we have clinical trials … label, phase 3 superiority trial of the European Mantle …